However, these studies all measured GDF-15 from ESRD patients already on maintenance hemodialysis, which implicates that this treatment may have an impact on the increased risk of atherosclerosis and heart failure leading to a higher mortality compared to the point at the start of hemodialysis. This evidence concerns the gene GDF15 and heart failure.